Table 2.
Study | Country | N | Measure used | Time of data collection | Worsening cognition | Worsening psychological symptoms | Worsening ADL | Changes in pharmacological therapy | Quality Score (max 8) |
---|---|---|---|---|---|---|---|---|---|
El Haj et al. [31] | France | AD: 58†† | HADS |
During the Covid pandemic |
NR | Total% NR Depression: 0.005* Anxiety: 0.004* |
NR | NR | 6 |
O'Caoimh et al. [32] | Ireland | 162 | Online survey |
2 weeks up until end of June 2020 | 54% (memory) |
51% (mood) |
43% | NR | 6 |
††informants are patients/people living with cognitive impairment.
*p-value.